A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : TRAb / thyroid-stimulating hormone receptor antibody

[Related PubMed/MEDLINE]
Total Number of Papers: 52
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   TRAb  (>> Co-occurring Abbreviation)
Long Form:   thyroid-stimulating hormone receptor antibody
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 A Case Report of Concurrent Graves' Disease and Subacute Thyroiditis Following SARS-CoV-2 Vaccination: An Autoimmune/Inflammatory Syndrome (ASIA). ASIA, SAT, US
2022 A hypothyroid mother after subtotal thyroidectomy delivered a newborn with hyperthyroidism from fetal stage: a case report. ---
2022 Comprehensive Analysis of lncRNA Expression Profile and the Potential Role of ENST00000604491 in Graves' Disease. FOXP1, GD, IKZF3, lncRNAs, PBMCs, ROC
2022 Graves' Disease with Thymic Hyperplasia: The Response of the Thyroid Function, Thyrotropin Receptor Autoantibody, and Thymic Size to Thiamazole Treatment. ---
2022 Stability of Anti-thyroid Stimulating Hormone Receptor Antibody in Whole Blood and Serum: Caution Required for Reflective and Batch Testing. ---
2022 Timing of Graves' Hyperthyroidism Management in Pregnant Women: Impact on the Infant Thyroid Volume. ATDs, GD
2022 Utility of Antibodies in the Diagnoses of Thyroid Diseases: A Review Article. Anti-TPO antibodies, CTLA, GD, HLA, HT, TPO, TSGT
2022 Utility of TSH Receptor Antibodies in the Differential Diagnosis of Hyperthyroidism in Clinical Practice. GD, NGD, ROC
2021 A Neonate with a Diagnosis of Pontocerebellar Hypoplasia Type 6 Treated with Biotin and Developed Biotin Interference with Laboratory Thyroid Function Tests. PCH6
10  2021 Clinical Course of Euthyroid Subjects With Positive TSH Receptor Antibody: How Often Does Graves' Disease Develop? GD
11  2021 Clinical efficacy of thyroid-stimulating immunoglobulin detection for diagnosing Graves' disease and predictors of responsiveness to methimazole. AIT, GD, GO, HS, ROC, TSI
12  2021 Hemodynamic Instability during Thyroidectomy in Graves' Disease. ATDs, GD
13  2021 Local immune microenvironment of skin may play an important role in the development of pretibial myxedema. GD, iSALT, PTM, TSHR
14  2021 Serum thyroid-stimulating hormone receptor antibody levels and thyroid dysfunction after hysterosalpingography: a case-control study. HSG
15  2021 The association between serum adenosine deaminase levels and Graves' disease. ADA, GD, HC, TPOAb, TSH
16  2020 A case report of thyroid-associated Orbitopathy with elevated TPO antibodies. anti-TPO, GD, HT, TAO
17  2020 A prospective randomized controlled clinical trial of Pingmu Decoction combined with acupuncture in the treatment of non-active thyroid-related ophthalmopathy. ebm, TSH
18  2020 Analytical performance evaluation of thyroid-stimulating hormone receptor antibody (TRAb) immunoassays. AMR, FAS, GD, TSHR
19  2020 Fetal goiter identified in a pregnant woman with triiodothyronine-predominant graves' disease: a case report. ---
20  2020 Management of thyrotoxicosis during pregnancy. ATD
21  2020 New-onset graves' disease after the initiation of nivolumab therapy for gastric cancer: a case report. ICIs, irAEs, TSAb
22  2019 A Case Report of Graves' Disease Induced by the Anti-Human Programmed Cell Death-1 Monoclonal Antibody Pembrolizumab in a Bladder Cancer Patient. anti-PD-1, GD
23  2019 Analysis in Choroidal Thickness in Patients with Graves' Ophthalmopathy Using Spectral-Domain Optical Coherence Tomography. CAS, CT, GD, GO, SD-OCT, TSH
24  2019 Comparison of the New, Rapid, and Fully Automated Kryptor TSH receptor Antibodies Assay (B.R.A.H.M.S.) with the Radioimmunological Assay (B.R.A.H.M.S.). ---
25  2019 Reduced Retinal Microvascular Density Related to Activity Status and Serum Antibodies in Patients with Graves' Ophthalmopathy. CAS, GO, OCTA, RCD, TAZ
26  2019 Thyroid-stimulating hormone receptor antibodies during follow-up as remission markers in childhood-onset Graves' disease treated with antithyroid drugs. ATD
27  2018 Study of Deiodinase Type 2 Polymorphisms in Graves' Disease and Ophthalmopathy in a Swedish Population. DIO2, FT3, FT4, GD, GO, SNPs, TPOAb
28  2017 Analytical and Clinical Validation of Two Commercially Available Immunoassays Used in the Detection of TSHR Antibodies. hCG, TSHR, TSI
29  2017 Prediction of thyroidal 131I effective half-life in patients with Graves' disease. ADP, RAIU, Teff
30  2017 Thymic Involution After Radioiodine Therapy for Graves Disease: Relationships With Serum Thyroid Hormones and TRAb. CT
31  2016 Is modified clinical activity score an accurate indicator of diplopia progression in Graves' orbitopathy patients? CAS, EOM, GO
32  2016 Management of Fetal and Neonatal Graves' Disease. ATD
33  2015 Correlation of normal thyroid ultrasonography with thyroid tests. FT4, TgAb, TPOAb, TSH, US
34  2015 Synergistic combined effect between CD40-1C>T and CTLA-4+6230G>A polymorphisms in Graves' disease. GD
35  2014 Autoimmunity and pulmonary hypertension in patients with Graves' disease. PVR
36  2014 Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers. ATD
37  2014 Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves' disease and type 1 diabetes mellitus: a case report. APS, GD, RTX, T1DM
38  2014 There is no elevation of immunoglobulin e levels in Albanian patients with autoimmune thyroid diseases. ATD, IgE
39  2013 Antenatal management of recurrent fetal goitrous hyperthyroidism associated with fetal cardiac failure in a pregnant woman with persistent high levels of thyroid-stimulating hormone receptor antibody after ablative therapy. ---
40  2012 [Association of TNF-alpha gene polymorphisms with Graves disease susceptibility and early course thyroid stimulating hormone receptor antibody level in Chinese Han population in Anhui region]. GD, TNF-alpha
41  2011 A genome-wide association study identifies two new risk loci for Graves' disease. ---
42  2010 Qualitative and quantitative impact of protective glucocorticoid therapy on the effective 131I half-life in radioiodine therapy for Graves disease. ---
43  2010 Thyroid hormones, their carrier proteins, and thyroid antibodies in the pleural effusion of two patients with graves' disease-induced thyrotoxicosis. ALB, TBG, TBPA
44  2008 Age influences the severity of Graves' ophthalmopathy. ---
45  2008 No association between Fas A/G polymorphism and therapeutic effects induced by methimazole treatment for Graves' disease in Northern Chinese. GD, MMI
46  2005 Determination of the levels of anti-thyroid-stimulating hormone receptor antibody with thyroid peroxidase antibody in Omani patients with Graves' disease. GD, SLE, TPO
47  2005 Elevation of serum adiponectin levels in Basedow disease. ---
48  2005 Evaluation of management of Graves' disease in District General Hospital: achievement of consensus guidelines. ---
49  2003 [Significance of combining tests of thyroid autoantibodies in differential diagnosis between Graves's disease and Hashimoto's hyperthyroidism]. FNB, sTSH, TGA, TMA, TPOAb
50  2000 [Neonatal hyperthyroidism in a premature infant born to a mother with Grave's disease]. ---
51  1994 Clinical evaluation of biotin-binding immunoglobulin in patients with Graves' disease. BBI, MCAb, TgAb
52  1993 Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose. ATD, GD